Abstracts tagged "giant cell arteritis"

Abstract Number: 1414 • ACR Convergence 2021
The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States
Mark Matza¹, Karina Torralba² and Minna Kohler³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Expedited referral systems or “fast-track” clinics incorporating vasculitis ultrasound (VUS) into the evaluation of patients with suspected giant cell arteritis (GCA) have shown reduced…
Abstract Number: 1398 • ACR Convergence 2021
Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis
Alojzija Hocevar¹, Rok Jese¹, Jelka Kramaric², Matija Tomšič³ and Ziga Rotar³, ¹UKC Ljubjana, Ljubjana, Slovenia, ²UKC Ljubjana, Ljubjana, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in…
Abstract Number: 1415 • ACR Convergence 2021
Temporal Artery Biopsy Reports Can Be Accurately Classified by Artificial Intelligence
Christopher McMaster¹, Victor Yang¹, Benjamin Sutu², Shereen Oon³, Gene-Siew Ngian³, Ian Wicks³, Russell Buchanan⁴ and David Liew¹, ¹Austin Health, Heidelberg, Australia, ²Melbourne Health, South Yarra, Australia, ³Melbourne Health, Parkville, Australia, ⁴Austin Health, Heidelberg, Melbourne, Australia
Background/Purpose: Studies of giant cell arteritis (GCA) rely on classifying temporal artery biopsies (TABs), the gold-standard diagnostic test. However, these results exist as free text,…
Abstract Number: 0151 • ACR Convergence 2021
Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis
Juan Molina¹, Isabel Castrejón², Javier Rivera², Julia Martínez Barrio², Juan Carlos Nieto², Katerine López², Fernando Montero², Laura Trives Folguera², Carlos González³ and Jose Maria Alvaro-Gracia², ¹Hospital General Universitario Gregorio Maran, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Ultrasound (US) is recommended as the first imaging modality to assess patients presenting with predominantly cranial symptoms of giant cell arteritis (GCA). However, its…
Abstract Number: 1399 • ACR Convergence 2021
Validation of a Giant Cell Arteritis Probability Score
Charlie Oshinsky¹, Alison Bays¹, Ingeborg Sacksen², Elizabeth Jernberg³, Eugene zierler¹, Andreas Diamantopoulos⁴ and Scott Pollock¹, ¹University of Washington, Seattle, WA, ²University of Washington, Bellingham, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Akerhus University Hospital, Brum, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis. Failure to rapidly diagnose and treat patients with GCA can result in irreversible…
Abstract Number: 1416 • ACR Convergence 2021
Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
Idil Esen¹, Philip Therkildsen², Berit Dalsgaard Nielsen², Anna van 't Ende¹, Annemieke Boots¹, Peter Heeringa¹, Ellen-Margrethe Hauge², Elisabeth Brouwer¹ and Yannick van Sleen³, ¹University Medical Center Groningen, Groningen, Netherlands, ²Aarhus University Hospital, Aarhus, Denmark, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…
Abstract Number: 0163 • ACR Convergence 2021
Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry
Eugenio De Miguel¹, Jesús T. Sánchez-Costa², Javier Narvaez³, Miguel Ángel gonzalez-Gay⁴, Noemí Garrido-Puñal⁵, Paula V. Estrada-Alarcon⁶, Iñigo Hernández-Rodríguez⁷, Elisa Fernández-Fernández⁸, María T. Silva-Diaz⁹, Jesús A. Valero-Jaimes¹⁰, Ismael González-Fernández¹¹, Julio Sánchez¹², Judit Lluch¹³, Eva Galindez-Agirregoikoa¹⁴, Javier Mendizábal-Mateos¹⁵, Luis Rodriguez Rodriguez¹⁶, Javier Loricera García¹⁷, Alejandro Muñoz¹⁸, Santos Castañeda¹⁹, Patricia Moya²⁰, Patricia Morán-Álvarez²¹, Vanessa A. Navarro-Angeles⁶, Joan Calvet-Fontova²², Ivette Casafont²³, Francisco Ortiz-Sanjuán²⁴, Selene Labrada-Arrabal²⁵, Cristina Campos-Fernández²⁶, María Alcalde-Villar²⁷, Antonio Juan-Mas²⁸ and Ricardo Blanco²⁹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁶Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁹Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ¹⁰Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ¹¹Hospital Universitario de León, León, Spain, ¹²Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ¹⁴Hospital Universitario de Basurto, Bilbao, Spain, ¹⁵H. Navarra, Navarra, Spain, ¹⁶Hospital Clinico San Carlos, Madrid, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁸Hospital Universitario Virgen del Rocío, Sevial, Spain, ¹⁹Hospital Universitario de la Princesa, Madrid, Spain, ²⁰Hospital Sant Pau, Barcelona, Spain, ²¹Hospital Universitario Ramón y Cajal, Madrid, Spain, ²²Hospital Universitari Parc Tauli, Sabadell, Spain, ²³Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ²⁴H. La Fe, Valencia, Spain, ²⁵Hospital del Mar, Barcelona, Spain, ²⁶Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁷Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: To standardize research studies different classification systems are used. Currently, the ACR Giant Cell Arteritis (GCA) 19901 classification criteria is probably the most widely…
Abstract Number: 1400 • ACR Convergence 2021
Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study
Karin Wadström¹, Jan-Åke Nilsson¹, Aladdin Mohammad², Kenneth Warrington³, Eric Matteson⁴, Magnus Jakobsson², Lennart Jacobsson⁵ and Carl Turesson⁶, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵University of Gothenburg, Gothenburg, Sweden, ⁶Lund University, Malm, Sweden
Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…
Abstract Number: 1417 • ACR Convergence 2021
Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors
Christopher McMaster¹, Victor Yang¹, Russell Buchanan² and David Liew¹, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Heidelberg, Melbourne, Australia
Background/Purpose: To determine whether an eventual diagnosis of giant cell arteritis in both temporal artery biopsy positive and negative patients can be identified using prospective…
Abstract Number: 0466 • ACR Convergence 2021
Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica
Eugenio De Miguel¹, Pierluigi Macchioni², Edoardo Conticini³, Corrado Campochiaro⁴, Rositsa Karalilova⁵, Giulia Klinowski², Paolo Falsetti³, Irene Monjo⁶, Alessandro Tomelleri⁷, Zguro Batalov⁵ and Alojzija Hocevar⁸, ¹Hospital Universitario La Paz, Madrid, Spain, ²Department of Rheumatology, IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ³Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan. Italy, Milan, Italy, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶Hospital La Paz - IdiPAZ, Madrid, Spain, ⁷Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan, Milan, Italy, ⁸UKC Ljubjana, Ljubjana, Slovenia
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of GCA patients1, however the frequency…
Abstract Number: 1401 • ACR Convergence 2021
Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab
Sebastian Unizony¹, Maria C. Cid², Daniel Blockmans³, Elisabeth Brouwer⁴, Lorenzo Dagna⁵, Bhaskar Dasgupta⁶, Bernhard Hellmich⁷, Eamonn Molloy⁸, Carlo Salvarani⁹, Bruce Trapnell¹⁰, Kenneth Warrington¹¹, Ian Wicks¹², Manoj Samant¹³, Teresa Zhou¹³, Lara Pupim¹³ and John F Paolini¹³, ¹Vasculitis and Glomerulonephritis Center, Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, ³General Internal Medicine, UZ Leuven, Leuven, Belgium, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Lombardia, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Internal Medicine, Rheumatology, and Immunology, Medius Kliniken, Kirchheim unter Teck, Germany, ⁸St Vincent's University Hospital, Dublin, Ireland, ⁹Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁰Translational Pulmonary Science Center, Cincinnati Children’s Hospital, Cincinnati, ¹¹Mayo Clinic, Rochester, Minnesota, ¹²Walter & Eliza Hall Institute & Melbourne Health, Melbourne, Australia, ¹³Kiniksa Pharmaceuticals Corp., Lexington, MA
Background/Purpose: Although giant cell arteritis (GCA) relapse is mostly defined by the recurrence of GCA signs/symptoms, in patients treated only with glucocorticoids, the C-reactive protein…
Abstract Number: 1418 • ACR Convergence 2021
Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen¹, Kornelis van der Geest², Annemieke Boots², Maria Sandovici² and Elisabeth Brouwer², ¹University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…
Abstract Number: 0502 • ACR Convergence 2021
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Benjamin Hur¹, Matthew Koster¹, Jin Sung Jang¹, Kenneth Warrington² and Jaeyun Sung¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota
Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
Abstract Number: 1402 • ACR Convergence 2021
Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy
Diana Prieto-Peña¹, Isabel Martínez-Rodríguez¹, Belén Atienza-Mateo², FRANCISCO JAVIER Gómez De La Fuente¹, Aida Sánchez-Salmón¹, Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large vessel vasculitis (LVV)-Giant Cell Arteritis (LVV-GCA) (1-2). 18F-fluodeoxyglucose positron emission tomography (18F-FDG PET/CT) is useful to assess…
Abstract Number: 1419 • ACR Convergence 2021
Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
Mwidimi Ndosi¹, Celia Almeida², Jill Dawson³, Emma Dures², Rosemary Greenwood⁴, Catherine Guly⁵, Sarah Mackie⁶, Alison Bromhead⁴, Steve Stern⁴ and Joanna Robson², ¹University of the West of England, Bristol, Filton, United Kingdom, ²UWE Bristol, Bristol, United Kingdom, ³University of Oxford, Oxford, ⁴University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ⁵University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, ⁶School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].